How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/mixed-anxiety-and-depressive-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mixed anxiety and depressive disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mixed anxiety and depressive disorder (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mixed anxiety and depressive disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xanax	alprazolam	Generic (originally Upjohn/Pfizer)	Benzodiazepine (triazolobenzodiazepine)	Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4	1981-10-16
Endep	AMITRIPTYLINE	AstraZeneca	Tricyclic Antidepressant	Histamine H1 receptor	1961-01-01
Chlordiazepoxide Hydrochloride	CHLORDIAZEPOXIDE	Bausch Health	Benzodiazepine	Histamine H1 receptor	1960-01-01
Amitryptiline	Amitryptiline	Mahatma Gandhi Institute of Medical Sciences		Aldehyde oxidase, 5-hydroxytryptamine receptor 6, D(1B) dopamine receptor
Xanax	Xanax	National Taiwan University Hospital		Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Mixed anxiety and depressive disorder
AstraZeneca · 1 drug in Mixed anxiety and depressive disorder
Bausch Health · 1 drug in Mixed anxiety and depressive disorder
Generic (originally Upjohn/Pfizer) · 1 drug in Mixed anxiety and depressive disorder
Mahatma Gandhi Institute of Medical Sciences · 1 drug in Mixed anxiety and depressive disorder
National Taiwan University Hospital · 1 drug in Mixed anxiety and depressive disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mixed anxiety and depressive disorder:

Cite this brief

Drug Landscape (2026). Mixed anxiety and depressive disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mixed-anxiety-and-depressive-disorder. Accessed 2026-06-10.

Mixed anxiety and depressive disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing